Pharmacol 2009;158(3):693–705 39 Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 2007;115(21):2689–2696 40 Jacobs LG Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly Clin Geriatr Med 2006;22(1):17–32 [vii–viii] 41 Streif W, Andrew M, Marzinotto V, et al Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients Blood 1999;94(9):3007–3014 42 Shehab N, Sperling LS, Kegler SR, Budnitz DS National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin Arch Intern Med 2010;170(21):1926–1933 43 Limdi NA, Wadelius M, Cavallari L, et al Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups Blood 2010;115(18):3827–3834 44 Gage BF, Eby C, Johnson JA, et al Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin Clin Pharmacol Ther 2008;84(3):326–331 45 International Warfarin Pharmacogenetics C, Klein TE, Altman RB, et al Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 2009;360(8):753–764 46 Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE Genetic warfarin dosing: tables versus algorithms J Am Coll Cardiol 2011;57(5):612–618 47 Nowak-Gottl U, Dietrich K, Schaffranek D, et al In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes Blood 2010;116(26):6101–6105 48 Vear SI, Ayers GD, Van Driest SL, et al The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population Br J Haematol 2014;165(6):832– 835 49 Biss TT, Avery PJ, Brandao LR, et al VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children Blood 2012;119(3):868–873 50 Shaw K, Amstutz U, Hildebrand C, et al VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children Pediatr Blood Cancer 2014;61(6):1055–1062 51 Hamberg AK, Wadelius M Pharmacogeneticsbased warfarin dosing in children Pharmacogenomics 2014;15(3):361–374 52 Moreau C, Bajolle F, Siguret V, et al Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement Blood 2012;119(3):861–867 53 Marek E, Momper JD, Hines RN, et al Prediction of warfarin dose in pediatric patients: an evaluation of the predictive performance of several models J Pediatr Pharmacol Ther 2016;21(3):224–232 54 Kazui M, Nishiya Y, Ishizuka T, et al Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 2010;38(1):92–99 55 Dansette PM, Rosi J, Bertho G, Mansuy D Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer Chem Res Toxicol 2012;25(2):348–356 56 Brandt JT, Close SL, Iturria SJ, et al Common polymorphisms of CYP2C19 and CYP2C9 ... tables versus algorithms J Am Coll Cardiol 2011;57(5):612–618 47 Nowak-Gottl U, Dietrich K, Schaffranek D, et al In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes... Blood 2012;119(3):861–867 53 Marek E, Momper JD, Hines RN, et al Prediction of warfarin dose in pediatric patients: an evaluation of the predictive performance of several models J Pediatr Pharmacol Ther